Further to this, tumors carrying a high mutational burden provide the immune system with neoantigens to mount such responses against, underscored by the observation that tumor mutational burden correlates with clinical benefit of ICIs targeting PD-1 and CTLA-4 (55–57). Here, CTLA4 is linked to neoplasm.